Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epelsiban PK/PD and Uterine Contractility Study
NCT02213029Phase 1Terminated
- Sponsor
- GSK
- Start
- Aug 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of epelsiban in infertility (3 arms), sponsored by GSK. Primary endpoints: The effect of the infused oxytocin dose on the time course of the frequency of endometrial contractions in Cohort 1, Frequency of endometrial contractions in Cohorts 2A, 2B and 2C and 3 more. Started Aug 2014; status: terminated.
02
Drugs
epelsiban
03
Conditions
infertility
Beyond the preview
Go deeper on NCT02213029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213029.